[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579450":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":18,"locations":29,"responsibleParty":50,"collaborators":18,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":18,"eligibilityCriteria":58,"healthyVolunteers":55,"sex":59,"minAge":60,"maxAge":18,"enrollmentInfo":61,"targetDuration":18,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":31,"whyStopped":18,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Stanford University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Group","EXPERIMENTAL","Participants receive Dipyridamole in addition to standard post-transplant care.",[13],"Drug: Dipyridamole 75 MG",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Group","NO_INTERVENTION","Participants in this group will receive standard post-transplant care without Dipyridamole.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Dipyridamole 75 MG","Dipyridamole administered three times daily when serum phosphorus levels fall below 4 mg\u002FdL. The drug is used off-label for this study to manage hypophosphatemia in kidney transplant recipients.",[9],[26],{"name":27,"affiliation":5,"role":28},"Stephan Busque, MD","PRINCIPAL_INVESTIGATOR",[30],{"facility":5,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Stanford","California","94304","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-122.16608,37.42411,{"lat":41,"lon":40},[44,49],{"name":45,"role":46,"phone":47,"phoneExt":18,"email":48},"Pari Waghela, MS","CONTACT","650-724-8441","pariw@stanford.edu",{"name":27,"role":28,"phone":18,"phoneExt":18,"email":18},{"type":28,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Stephan Busque","Professor of Surgery (Abdominal Transplantation)","100579450","phase-2-evaluation-of-dipyridamole-in-preventing-post-transplant-hypophosphatemia-in-kidney-transplant-recipients-100579450",false,"NCT06824454","Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients","Inclusion Criteria:\n\n* Adult kidney transplant patients.\n* No known contraindications to Dipyridamole\n\nExclusion Criteria:\n\n* Contraindications to Dipyridamole.\n* Patients with delayed graft function (defined as the need for dialysis within seven days post-transplantation).\n* Patients requiring Plavix, direct oral anticoagulants (DOACs), or Coumadin.","ALL","18 Years",{"count":62,"type":63},90,"ESTIMATED","INTERVENTIONAL",[66],"PHASE2","The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.",[69,70],"Hypophosphatemia","Kidney Transplantation",[72,73,74,75,76,77,78],"Post-kidney transplant care","Dipyridamole","Renal phosphate loss","Serum phosphate levels","Phosphate supplementation","Transplant graft function","Kidney transplant complications","2026-06-09",{"date":81,"type":82},"2026-06-11","ACTUAL",{"date":84,"type":82},"2025-05-15",{"date":86,"type":63},"2027-05",{"name":5,"class":6},1]